Maternal hyperuricemia and adverse neonatal outcomes in normotensive pregnancies: Evidence from a prospective cohort study in Eastern Uganda
PLOS One · 02.03.2026 · 21 (3) · e0342913
DOI: 10.1371/journal.pone.0342913 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, online erschienen am 02.03.2026. Verfasst von Hassan Abdullahi Hafsa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kampala International University, Ishaka, Uganda. Hauptthemen laut MEDLINE: Hyperuricemia, Pregnancy Outcome, Pregnancy Complications. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Maternal hyperuricemia is a potential biomarker of adverse pregnancy outcomes, but evidence among normotensive women in low- and middle-income countries is limited. We aimed to assess the association between elevated maternal serum uric acid (SUA) levels and adverse neonatal outcomes.
Methods
We conducted a prospective cohort study at Jinja Regional Referral Hospital, Uganda, from 1 st October 2024–1 st February 2025, enrolling 352 normotensive women in latent labor. SUA was measured using gestational-age–specific cutoffs, classifying women as hyperuricemic or normouricemic. Outcomes included preterm birth, small-for-gestational-age (SGA) birth, stillbirth, and low Apgar score. Poisson regression with robust standard errors estimated adjusted relative risks (aRR) and 95% confidence intervals.
Results
Adverse neonatal outcomes occurred in 37.5% of participants. Hyperuricemic women had significantly higher composite risk (62.5% vs. 12.5%; aRR = 4.32, 95% CI 2.92–6.39). Hyperuricemia independently predicted preterm birth (aRR = 3.63, 95% CI 1.70–7.72), SGA (aRR = 2.80, 95% CI 1.61–4.86), and stillbirth (aRR = 5.00, 95% CI 1.47–16.99). Maternal age ≥ 40 years, low education, < 4 antenatal visits, previous preterm birth, previous stillbirth, and obesity were also associated with adverse outcomes.
Conclusions
Maternal hyperuricemia is a strong predictor of preterm birth, SGA, and stillbirth. Routine SUA screening during antenatal care, combined with closer monitoring of high-risk women, could help improve neonatal outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Kampala International University, Ishaka, Uganda.
- Department of Pediatrics and Child Health, Kampala International University, Ishaka, Uganda.
- Department of Surgery, Kampala International University, Ishaka, Uganda.
- Department of Sciences, University of Rwanda, Kigali, Rwanda.
ORCID-Profile: Theoneste Hakizimana
Zitieren
APA
Hafsa, H. A., Sabine Ishimwe, M. P., Kasujja, M., Okot, G., Sheikh Isse, S. A., Hamdi, H. M., Sadia, M. M., Ali, R. A., Suliman Ebaid, A. A., Okello, M., Kazigo, A. K., Nteziyaremye, T., Bwaga, I., & Hakizimana, T. (2026). Maternal hyperuricemia and adverse neonatal outcomes in normotensive pregnancies: Evidence from a prospective cohort study in Eastern Uganda. PLOS One, 21(3), e0342913. https://doi.org/10.1371/journal.pone.0342913
Vancouver
Hafsa HA, Sabine Ishimwe MP, Kasujja M, Okot G, Sheikh Isse SA, Hamdi HM, et al. Maternal hyperuricemia and adverse neonatal outcomes in normotensive pregnancies: Evidence from a prospective cohort study in Eastern Uganda. PLOS One. 2026;21(3):e0342913. doi:10.1371/journal.pone.0342913
BibTeX
@article{Hafsa2026,
author = {Hafsa, Hassan Abdullahi and Sabine Ishimwe, Marie Pascaline and Kasujja, Musa and Okot, Geoffrey and Sheikh Isse, Sawda Abdikarim and Hamdi, Hussein Mire and Sadia, Mohamud Mohamed and Ali, Ramlo Abdi and Suliman Ebaid, Adam Abdrahim and Okello, Maxwell and Kazigo, Ahmed Kiswezi and Nteziyaremye, Theodore and Bwaga, Ibrahim and Hakizimana, Theoneste},
title = {Maternal hyperuricemia and adverse neonatal outcomes in normotensive pregnancies: Evidence from a prospective cohort study in Eastern Uganda},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0342913},
doi = {10.1371/journal.pone.0342913}
}
EUVIMED